● Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Condition: Progressive Metastatic Castrate Resistant Prostate Cancer · Sponsor: Novartis Pharmaceuticals

PhasePhase 1/Phase 2

Planned participants188

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Always discuss trial participation with your own doctor first.

Locations (33)

Sarah Cannon Research Institute	Denver, Colorado, United States	Recruiting
Sarah Cannon Research Institute	Jacksonville, Florida, United States	Recruiting
Emory University	Atlanta, Georgia, United States	Recruiting
Wichita Urology Group PA	Wichita, Kansas, United States	Recruiting
Mass General Hospital	Boston, Massachusetts, United States	Recruiting
Cleveland Clinic Foundation	Cleveland, Ohio, United States	Recruiting
Fred Hutchinson Cancer Research Center	Seattle, Washington, United States	Recruiting
Novartis Investigative Site	St Leonards, New South Wales, Australia	Recruiting
Novartis Investigative Site	Melbourne, Victoria, Australia	Recruiting
Novartis Investigative Site	Liverpool, Australia	Recruiting
Novartis Investigative Site	Halifax, Nova Scotia, Canada	Recruiting
Novartis Investigative Site	Beijing, China	Recruiting

+ 21 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07206056